The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Drobizhev M.Yu.

Cardiology clinic of the I.M. Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

Fedotova A.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Kikta S.V.

FGBU "Poliklinika #3" Upravleniia delami Prezidenta RF, Moskva

Rationale for the choice of medication based on the conception of the pathogenesis of mental disorder and mechanism of drug action

Authors:

Drobizhev M.Yu., Fedotova A.V., Kikta S.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2): 15‑21

DOI: 10.17116/jnevro201411411215-21

Read: 2970 times

Download PDF (RU)
Contact the author
Table of contents

RATIONALE FOR THE CHOICE OF MEDICATION BASED ON THE CONCEPTION OF THE PATHOGENESIS OF MENTAL DISORDER AND MECHANISM OF DRUG ACTION
RATIONALE FOR THE CHOICE OF MEDICATION BASED ON THE CONCEPTION OF THE PATHOGENESIS OF MENTAL DISORDER AND MECHANISM OF DRUG ACTION

To cite this article:

Drobizhev MYu, Fedotova AV, Kikta SV. Rationale for the choice of medication based on the conception of the pathogenesis of mental disorder and mechanism of drug action. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2):15‑21. (In Russ.)
https://doi.org/10.17116/jnevro201411411215-21

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Factors affe­cting the quality of life of patients with neurological mani­festations of post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):44-50
EEG features in young female patients with depressive states at different stages of endo­genous mental diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):100-103
Impact of various reha­bilitation programs on anxiety and depression after surgery of early-stage cervical cancer. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):40-44
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Online phenotypes of depression symptoms are asso­ciated with poly­genic risk scores of soma­tic diseases in a popu­lation-based cohort. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):122-131
Asso­ciation between the vita­min D level and depression in the elde­rly people in the Euro­pean North of Russia. Russian Journal of Preventive Medi­cine. 2024;(12):107-113
Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspe­cts and patient mana­gement tactics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):744-752
Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):57-61
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Abstract:

In modern medicine, when prescribing drugs it is customary to take into account the pathogenesis of the disease and the mechanism of action of drugs. On the example of buspirone, authors have shown that in psychiatry recommendations for administration of drugs should also consider the pathogenesis of diseases (disorders) and the mechanism of drug action. These data will contribute to the rapprochement of neurology and psychiatry with other medical specialties.

Keywords:

anxiety disorders
anxiety disorders
depression
depression
psychopharmacology
psychopharmacology
neurology
neurology
buspirone
buspirone

Authors:

Drobizhev M.Yu.

Cardiology clinic of the I.M. Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

Fedotova A.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Kikta S.V.

FGBU "Poliklinika #3" Upravleniia delami Prezidenta RF, Moskva

Close metadata

References:

  1. Essentsial'naya arterial'naya gipertenziya (gipertonicheskaya bolezn') http://www.cardioportal.ru/amosovakardio11/58.html
  2. Diagnostika i lechenie arterial'noi gipertenzii. http://www.scardio.ru/content/images/recommendation/nacionalnye_rekomendacii_po_diagnostike_i_lecheniyu_arterialnoy_gipertonii2008.pdf
  3. Drobizhev M.Yu., Kikta S.V., Fedotova A.V., Serdyuk O.V. Prosto depressiya. Voprosy i otvety. M: OOO "Marketingovaya Mashina" 2013; 100.
  4. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976; 133: 197-202.
  5. Stahl S.M. Stahl's essential psychopharmacology: neuroscientific basis and practical application. 3 nd ed. Cambridge University Press 2008; 1117.
  6. Smulevich A.B., Syrkin A.L., Drobizhev M.Yu., Ivanov S.V. Psikhokardiologiya. M: Med inform agent 2005; 784.
  7. Klinicheskaya farmakologiya: uchebnik dlya vuzov. Pod red. V.G. Kukesa. 4-e izd. 2009; 1056.
  8. Psikhiatriya: spravochnik prakticheskogo vracha. Pod. red. A.G. Gofmana. 2-e izd., pererab. M: MEDpressinform 2010; 608.
  9. Terapiya antidepressantami i drugie metody lecheniya depressivnykh rasstroistva. Doklad Rabochei gruppy CINP na osnove obzora dokazatel'nykh dannykh. Pod red. V.N. Krasnova. M 2008; 215.
  10. Spravochnik Vidal'. Lekarstvennyi preparaty. http://www.vidal.ru/
  11. Mezhdunarodnaya klassifikatsiya boleznei 10-i peresmotr. http://mkb-10.rf/
  12. Drobizhev M.Yu., Fedotova A.V., Kikta S.V. Patogeneticheskaya farmakoterapiya fobicheskikh trevozhnykh rasstroistv i sostoyanii, obuslovlennykh stressom. Profilakticheskaya meditsina 2013; 4: 34-39.
  13. Gobert A., Rivet J.M., Cistarelli L., Melon C., Millan M.J. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 1999; 93: 4: 1251-1262.
  14. Loane C., Politis M. Buspirone: what is it all about? Brain Res 2012; 1461: 111-118.
  15. Berger A., Mychaskiw M., Dukes E., Edelsberg J., Oster G. Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. BMC Geriatr 2009; 9: 31.
  16. Campbell Burton C.A., Holmes J., Murray J., Gillespie D., Lightbody C.E., Watkins C.L., Knapp P. Interventions for treating anxiety after stroke. Cochrane Database Syst Rev 2011; 12: CD008860.
  17. Lee S.T., Park J.H., Kim M. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache 2005; 45: 8: 1004-1011.
  18. Tack J., Janssen P., Masaoka T., Farré R., Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10: 11: 1239-1245.
  19. Davari-Ashtiani R., Shahrbabaki M.E., Razjouyan K., Amini H., Mazhabdar H. Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. Child Psychiatry Hum Dev 2010; 41: 6: 641-648.
  20. Mohammadi M.R., Hafezi P., Galeiha A., Hajiaghaee R., Akhondzadeh S. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study. Acta Med Iran 2012; 50: 11: 723-728.
  21. Sutherland S.M., Adler L.A., Chen C., Smith M.D., Feltner D.E. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012; 73: 4: 445-450.
  22. Bech P., Fava M., Trivedi M.H., Wisniewski S.R., Rush A.J. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012; 125: 4: 342-348.
  23. Fang Y., Yuan C., Xu Y., Chen J., Wu Z., Cao L., Yi Z., Hong W., Wang Y., Jiang K., Cui X., Calabrese J.R., Gao K. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011; 31: 5: 638-642.
  24. Green T.R. Bupropion for SSRI-induced fatigue. J Clin Psychiatry 1997; 58: 4: 174.
  25. Landén M., Eriksson E., Agren H., Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999; 19: 3: 268-271.
  26. Piskulić D., Olver J.S., Maruff P., Norman T.R. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. Hum Psychopharmacol 2009; 24: 6: 437-446.
  27. Lauterbach E.C., Victoroff J., Coburn K.L., Shillcutt S.D., Doonan S.M., Mendez M.F. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 2010; 22: 1: 8-18.
  28. Heo J.H., Lee S.T., Chu K., Kim M. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 2008; 271: 1-2: 87-90.
  29. Nag N., Tarlac V., Storey E. Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. Cerebellum 2013; 12: 1: 74-82.
  30. Holroyd-Leduc J.M., Liu B.A., Maki B.E., Zecevic A., Herrmann N., Black S.E. The role of buspirone for the treatment of cerebellar ataxia in an older individual. Can J Clin Pharmacol 2005; 12: 3: 218-221.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.